Literature DB >> 18389175

Actual status of AIDS-related lymphoma management in Japan.

Hirokazu Nagai1, Nami Iwasaki2, Takashi Odawara3, Seiji Okada4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18389175     DOI： 10.1007/s12185-008-0073-8

Source DB:  PubMed          Journal:  Int J Hematol        ISSN： 0925-5710            Impact factor:   2.490


× No keyword cloud information.
  7 in total

Review 1.  AIDS-related lymphoproliferative disease.

Authors:  Willis H Navarro; Lawrence D Kaplan
Journal:  Blood       Date:  2005-08-11       Impact factor: 22.113

2.  Better response to chemotherapy and prolonged survival in AIDS-related lymphomas responding to highly active antiretroviral therapy.

Authors:  A Antinori; A Cingolani; L Alba; A Ammassari; D Serraino; B C Ciancio; F Palmieri; A De Luca; L M Larocca; L Ruco; G Ippolito; R Cauda
Journal:  AIDS       Date:  2001-08-17       Impact factor: 4.177

3.  Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators.

Authors:  F J Palella; K M Delaney; A C Moorman; M O Loveless; J Fuhrer; G A Satten; D J Aschman; S D Holmberg
Journal:  N Engl J Med       Date:  1998-03-26       Impact factor: 91.245

4.  AIDS across Europe, 1994-98: the EuroSIDA study.

Authors:  A Mocroft; C Katlama; A M Johnson; C Pradier; F Antunes; F Mulcahy; A Chiesi; A N Phillips; O Kirk; J D Lundgren
Journal:  Lancet       Date:  2000-07-22       Impact factor: 79.321

5.  Changes in AIDS-related lymphoma since the era of highly active antiretroviral therapy.

Authors:  C Besson; A Goubar; J Gabarre; W Rozenbaum; G Pialoux; F P Châtelet; C Katlama; F Charlotte; B Dupont; N Brousse; M Huerre; J Mikol; P Camparo; K Mokhtari; M Tulliez; D Salmon-Céron; F Boué; D Costagliola; M Raphaël
Journal:  Blood       Date:  2001-10-15       Impact factor: 22.113

6.  Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010.

Authors:  Lawrence D Kaplan; Jeannette Y Lee; Richard F Ambinder; Joseph A Sparano; Ethel Cesarman; Amy Chadburn; Alexandra M Levine; David T Scadden
Journal:  Blood       Date:  2005-05-24       Impact factor: 22.113

7.  Highly effective treatment of acquired immunodeficiency syndrome-related lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology.

Authors:  Richard F Little; Stefania Pittaluga; Nicole Grant; Seth M Steinberg; Mark F Kavlick; Hiroaki Mitsuya; Genoveffa Franchini; Martin Gutierrez; Mark Raffeld; Elaine S Jaffe; Gene Shearer; Robert Yarchoan; Wyndham H Wilson
Journal:  Blood       Date:  2003-02-27       Impact factor: 22.113
  7 in total
  2 in total

1.  Clinical and pathological aspects of human immunodeficiency virus-associated plasmablastic lymphoma: analysis of 24 cases.

Authors:  Yusuke Koizumi; Tomoko Uehira; Yasunori Ota; Yoshihiko Ogawa; Keishiro Yajima; Junko Tanuma; Mihoko Yotsumoto; Shotaro Hagiwara; Satoshi Ikegaya; Dai Watanabe; Hitoshi Minamiguchi; Keiko Hodohara; Kenta Murotani; Hiroshige Mikamo; Hideho Wada; Atsushi Ajisawa; Takuma Shirasaka; Hirokazu Nagai; Yoshinori Kodama; Tsunekazu Hishima; Makoto Mochizuki; Harutaka Katano; Seiji Okada
Journal:  Int J Hematol       Date:  2016-09-07       Impact factor: 2.490

2.  Clinical characteristics of human immunodeficiency virus-associated Hodgkin lymphoma patients in Japan.

Authors:  Mihoko Yotsumoto; Shotaro Hagiwara; Atsushi Ajisawa; Junko Tanuma; Tomoko Uehira; Hirokazu Nagai; Yuko Fujikawa; Shunichi Maeda; Kiyoshi Kitano; Nobuyoshi Arima; Kenji Uno; Toshiki Iwai; Igen Hongo; Yasunori Ota; Katsuyuki Fukutake; Seiji Okada
Journal:  Int J Hematol       Date:  2012-07-01       Impact factor: 2.490
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.